Med最新文献

{"title":"Pomalidomide plus bortezomib and dexamethasone for newly diagnosed multiple myeloma with renal impairment: Randomized phase II study (POM-MM-003).","authors":"Fei Xiao, Liru Wang, Fei Li, Fang Wang, Yuping Zhong, Xiaoyan Qu, Chunkang Chang, Zhenyu Li, Yang Liu, Xuelin Dou, Lei Wen, Nan Peng, Jin Lu, Jian Hou","doi":"10.1016/j.medj.2026.101293","DOIUrl":"10.1016/j.medj.2026.101293","url":null,"abstract":"<p><strong>Background: </strong>POM-MM-003 study compared pomalidomide-bortezomib-dexamethasone (PVd) with Vd in newly diagnosed multiple myeloma (NDMM) patients with RI.</p><p><strong>Methods: </strong>POM-MM-003 was open-label, randomized, phase II study done at eight centers in China (ClinicalTrials.gov: NCT05432414). Patients with symptomatic NDMM with RI (creatinine clearance ≥15 to <60 mL/min) were randomly 2:1 to PVd and Vd groups for two 21-day induction cycles, followed by additional 2-cycle same treatment when achieving minor response. Primary endpoint was very good partial response or better (≥VGPR) after 4-cycle induction.</p><p><strong>Findings: </strong>Between January 18, 2023 and December 2, 2024, 82 patients were randomized to PVd (n = 58) and Vd (n = 24) groups. After 4-cycle induction, PVd resulted in a significantly higher ≥ VGPR rate (72.4% [42/58; 95% CI: 59.1-83.3] vs. 20.8% [5/24; 95% CI: 7.1-42.2]; p < 0.001) and renal response rate (75.9% [44/58; 95% CI: 62.8-86.1] vs. 45.8% [11/24; 95% CI: 25.6-67.2]; p = 0.009) versus Vd after 4-cycle induction. Median progression-free survival (PFS) and overall survival (OS) in both groups were not reached. Grade 3-4 treatment-related adverse events (TRAEs) occurred in 41.4% (24/58) of patients with PVd and 29.2% (7/24) with Vd. Only one case in the PVd group died of treatment-related ileus.</p><p><strong>Conclusions: </strong>PVd may represent a potential treatment option for this patient population.</p><p><strong>Funding: </strong>This trial was sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2021072900001) and was funded by the National Natural Science Foundation of China (no. 82370203), the Beijing Natural Science Foundation (no. 7264339), and the Peking University People's Hospital Scientific Research Development Funds (RDJP2025-06).</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101293"},"PeriodicalIF":13.3,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148921154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep learning-enabled screening of chronic kidney disease from echocardiography.","authors":"Victoria Yuan, Hirotaka Ieki, Alexander Sandhu, Long H Nguyen, Paul P Cheng, Stephanie T Chang, Andrew P Ambrosy, Alan C Kwan, Alan S Go, Susan Cheng, David Ouyang","doi":"10.1016/j.medj.2026.101296","DOIUrl":"10.1016/j.medj.2026.101296","url":null,"abstract":"<p><strong>Background: </strong>Chronic kidney disease (CKD) affects nearly 850 million individuals globally. The prevalence of undiagnosed CKD is over 60%.</p><p><strong>Methods: </strong>Taking advantage of the relationship between CKD and cardiovascular disease, we developed a deep learning (DL) model to detect CKD from parasternal long-axis (PLAX) videos, using 325,377 PLAX videos from 62,818 patients at Cedars-Sinai Medical Center (CSMC). We externally validated our model in two independent cohorts of 2,762 patients at Stanford Healthcare (SHC) and 41,611 patients at Kaiser-Permanente Northern California (KPNC).</p><p><strong>Findings: </strong>In a held-out test cohort at CSMC, our model detected any stage of CKD with an area under the curve (AUC) of 0.756 (95% confidence interval: 0.749-0.763), with consistently strong performance in the KPNC (AUC: 0.718 [0.714-0.723]) and SHC (AUC: 0.719 [0.704-0.735]) cohorts. Our model performed well across subgroups with and without metabolic comorbidities, suggesting that it learned imaging features specific to CKD.</p><p><strong>Conclusions: </strong>Our DL echo model detected CKD with robust performance at two external clinical sites, thus offering an avenue for noninvasive screening and improved detection rates.</p><p><strong>Funding: </strong>This work was supported by the Sarnoff Cardiovascular Research Foundation, the American Heart Association (25POST1357984 and 25AHAI1487693), and the National Institutes of Health (R00HL157421, R01HL173487, and R01HL173526).</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101296"},"PeriodicalIF":13.3,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149002688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mucoadhesive recombinant human catalase for dry eye disease: From protein engineering to first-in-human study.","authors":"Ming Shao, Yiteng Lu, Wenjie Xie, Annan Lu, Yutong Jiang, Xiaojing Chen, Yu Chai, Qihua Le, Lijia Tian, Yongyun Li, Jini Qiu, Kun Shan, Chenya Wang, Jiaxu Hong, Zhuang Liu","doi":"10.1016/j.medj.2026.101298","DOIUrl":"https://doi.org/10.1016/j.medj.2026.101298","url":null,"abstract":"<p><strong>Background: </strong>Oxidative stress caused by excess reactive oxygen species (ROS) plays a key role in the progression of dry eye disease (DED), yet no approved DED therapy directly eliminates ROS. Here, we develop an antioxidant biologic with enhanced ocular-surface retention by thiol engineering of recombinant human catalase (hCAT) as a new ROS-scavenging eye drop therapy for DED.</p><p><strong>Methods: </strong>Thiolated hCAT (hCAT-SH) was characterized for activity, stability, mucin interaction, and ocular retention. Efficacy, mechanism, and safety were evaluated in mouse, rabbit, and rat studies, followed by a randomized, double-blind, placebo-controlled first-in-human trial in 30 patients with DED.</p><p><strong>Findings: </strong>With formulation optimization, hCAT-SH maintained enzymatic activity and formulation stability, while exhibiting enhanced mucin binding and prolonged corneal retention. In mouse DED models, hCAT-SH reduced oxidative stress, accelerated epithelial repair, restored tear secretion, and modulated inflammatory and barrier-repair pathways distinct from cyclosporine. In rabbits, exposure remained predominantly ocular with favorable repeated-dose tolerability. Clinically, 0.1 mg/mL hCAT-SH significantly improved corneal fluorescein staining, reduced tear cytokine levels and corneal dendritic cell density versus placebo, and raised no treatment-related safety concerns.</p><p><strong>Conclusions: </strong>hCAT-SH is a carrier-free, long-retained H₂O₂-scavenging biologic, with integrated preclinical and first-in-human evidence supporting further development as a new DED drug.</p><p><strong>Funding: </strong>National Natural Science Foundation of China; National Technology Innovation Center for Biopharmaceuticals; Jiangsu Key R&D Program; National Key R&D Program of China; Shanghai \"Dawn\" Program; Shanghai Science and Technology Innovation Action Plans; Shanghai Municipal Commission of Health; Shanghai High-Quality Development Plan for Science and Technology Industry; and Macao FDCT.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101298"},"PeriodicalIF":13.3,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149002641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy-associated cardiac complications.","authors":"Sarah Thordsen, Zoltan Arany","doi":"10.1016/j.medj.2026.101301","DOIUrl":"https://doi.org/10.1016/j.medj.2026.101301","url":null,"abstract":"<p><p>Cardiovascular disease has become the most common cause of maternal mortality in the United States and non-obstetric cause of maternal mortality worldwide. Pregnancy profoundly alters maternal physiology and creates multiple maternal vulnerabilities, especially but not uniquely in women with preexisting cardiac disease. Common cardiac conditions represented in this patient population include arrhythmias, cardiomyopathies, and valvular heart disease, putting women at risk for numerous adverse events of pregnancy, including pre-eclampsia, heart failure, preterm delivery, and small-for-gestational-age babies. These complications often foretell long-term maternal cardiovascular risks and are also highly influenced by socioeconomic circumstances. To address these issues, cardio-obstetrics has emerged as a diverse and growing field spanning multiple medical specialties. Due to the breadth of pathology, a multidisciplinary Cardio-Obstetrics management team strategy is crucial. We review here common cardiac pathologies and their management throughout the peripartum period.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101301"},"PeriodicalIF":13.3,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149002593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An adult proteomic signature associated with very low birth weight and chronic disease risk.","authors":"Cho-Yi Huang, David Seong, Jonathan Reiss, Chi-Hung Shu, Mohammad Amin Sadeghi, Philip Chung, Liu K Yang, Lei Xue, Yaxin Fang, Rui Xu, Xiruo Ding, Saber Sheybani, Lichy Han, Bernard C Mawuli, Marc Ghanem, Mehrdad Kiamari, Alan L Chang, Tomin James, Samson J Mataraso, Camilo Espinosa, Eloise Berson, Po-Nien Tsao, Martin S Angst, Brice Gaudiliere, Lawrence Prince, Gary Shaw, David Stevenson, Nima Aghaeepour","doi":"10.1016/j.medj.2026.101297","DOIUrl":"https://doi.org/10.1016/j.medj.2026.101297","url":null,"abstract":"<p><strong>Background: </strong>Adults born at very low birth weight (VLBW, <1.5 kg) have elevated risks of chronic disease, but it is unclear whether adult plasma proteomics contains a detectable signature associated with recalled VLBW.</p><p><strong>Methods: </strong>We analyzed 2,923 plasma proteins in 26,061 UK Biobank participants (median sampling age 56.4 years) with recalled birth weight, including 368 with VLBW and 25,693 with normal birth weight. We derived a machine learning proteomic prematurity index (PPI) distinguishing these groups and evaluated associations with 425 adult diagnoses, discrimination relative to birth weight and electronic health record (EHR) information, incident diseases after proteomic sampling, and exploratory biological interpretation.</p><p><strong>Findings: </strong>The PPI was associated with recalled VLBW (odds ratio [OR], 7.32; 95% confidence interval [95% CI], 4.01-13.42) and remained independently associated after adjustment for EHR-derived VLBW probability (OR, 5.82; 95% CI, 3.99-8.47). Recalled VLBW was associated with adult disease burden, and PPI showed higher discrimination than birth weight for 370 of 425 diseases. Incident-only analyses preserved the cross-disease hazard ratio patterns, while fewer events and adult factor adjustment attenuated some associations. Exploratory biological annotations paralleled the disease patterns. Among participants with normal birth weight, higher PPI was associated with disease burden and subsequent disease risk, indicating that PPI is not VLBW specific.</p><p><strong>Conclusions: </strong>Adult plasma proteomics identifies a signature associated with recalled VLBW that provides information about adult disease risk beyond birth weight and EHR-derived measures. These findings are hypothesis generating and do not establish a direct molecular consequence of prematurity. External validation is required before clinical application.</p><p><strong>Funding: </strong>The March of Dimes, the Alfred E. Mann Foundation, the Universe of Mind, and the Bill & Melinda Gates Foundation (INV-037517 and INV-076306).</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101297"},"PeriodicalIF":13.3,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune-stromal interactions at the crossroads of tissue injury, repair, and tumor progression.","authors":"Derek Ning, Daniel Naveed Tavakol, Pamela L Graney, Ethan Lee, Clark T Hung, Gordana Vunjak-Novakovic","doi":"10.1016/j.medj.2026.101222","DOIUrl":"10.1016/j.medj.2026.101222","url":null,"abstract":"<p><p>Macrophage-fibroblast crosstalk plays a critical yet incompletely understood role in cancer, fibrosis, and tissue repair. A central challenge is capturing the diversity of these cells, whose phenotypes are shaped by microenvironmental cues and developmental origins. Macrophage heterogeneity reflects the tissue-resident and bone marrow-derived lineages, while fibroblasts adopt distinct subsets defined by tissue context. Myofibroblasts can emerge from fibroblasts, monocytes, and other stromal cells. The lack of markers to distinguish these subpopulations remains a major barrier to defining their specific roles in pathological outcomes, including tissue injury, repair, and cancer. Together, macrophages and fibroblasts maintain tissue homeostasis and drive repair; however, disruptions in their crosstalk promote fibrotic remodeling and tumor-permissive microenvironments. Here, we review the origins, diversity, and roles of non-parenchymal macrophages and fibroblasts in fibrosis and cancer, highlighting key gaps and future directions to advance the field.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101222"},"PeriodicalIF":13.3,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148550560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic ductal adenocarcinoma: Clinical trials to watch.","authors":"Vincent P Groot, I Quintus Molenaar, Geert A Cirkel, Christopher L Wolfgang, Hjalmar C Van Santvoort","doi":"10.1016/j.medj.2026.101268","DOIUrl":"10.1016/j.medj.2026.101268","url":null,"abstract":"<p><p>The treatment of PDAC is transitioning from uniform cytotoxic chemotherapy toward precision strategies guided by molecular identity and disease stage. RAS and PARP inhibitors and personalized neoantigen vaccination have created new options across metastatic and resectable disease. Chemotherapy timing relative to surgery and post-resection surveillance represent other important axes of precision oncology. Seven trials addressing these dimensions may collectively redefine PDAC treatment.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":"7 9","pages":"101268"},"PeriodicalIF":13.3,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148945752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Q&A with Raghib Ali.","authors":"Raghib Ali","doi":"10.1016/j.medj.2026.101221","DOIUrl":"https://doi.org/10.1016/j.medj.2026.101221","url":null,"abstract":"<p><p>Dr. Raghib Ali, OBE, is a clinical epidemiologist whose research is focused on the causes, prevention, and treatment of diseases and on reducing health inequalities. He has spent the last 20 years at the Universities of Oxford and Cambridge and at New York University working on similar studies, including UK Biobank and the UAE Healthy Future Study. He is also a consultant in acute medicine at the Oxford University Hospitals NHS Trust and an honorary consultant with the Office for Health Disparities and Improvement. He was awarded an OBE in the Queen's Birthdays Honours 2022 for services to the NHS and the COVID-19 response and was elected as an Honorary Fellow of the Faculty of Public Health in 2023.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":"7 9","pages":"101221"},"PeriodicalIF":13.3,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148945674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ketamine assisted psychotherapy to reduce chronic neuropathic pain: A mixed-methods randomized pilot trial.","authors":"Akash Goel, Calvin Diep, Ahnaf Zahin, Joshua D Rosenblat, Sérgio M Pereira, Bijan Teja, Kruthi Rao, Cheryl Pritlove, Kathryn Hodwitz, Hance Clarke, Joel Katz, Duminda N Wijeysundera, Janneth Pazmino-Canizares, Gabriella Mattina, Roshni Nayar, Zaaria Thomas, Kevin Dang, Karim S Ladha, Paul Ritvo","doi":"10.1016/j.medj.2026.101259","DOIUrl":"10.1016/j.medj.2026.101259","url":null,"abstract":"<p><strong>Background: </strong>Intravenous ketamine can provide short-term analgesia in chronic neuropathic pain but benefits often wane after treatment. We conducted a randomized pilot trial to assess the feasibility of combining ketamine infusions with psychotherapy to inform future efficacy trials.</p><p><strong>Methods: </strong>In this single-center, randomized, outcome-assessor-blinded pilot trial at a Canadian tertiary pain clinic, adults with moderate-to-severe chronic neuropathic pain were randomly assigned in 1:1:1 ratio to the ketamine, psychotherapy, or combined ketamine plus psychotherapy arm. Ketamine was delivered as three intravenous infusions over 16 weeks; psychotherapy consisted of 16 weekly cognitive behavioral therapy and mindfulness-based meditation sessions. The primary outcome was feasibility, assessed using prespecified progression criteria. Exploratory outcomes included changes in pain interference (PROMIS 6a T-score), pain intensity, mood, and qualitative interview findings at week 20 (ClinicalTrials.gov: NCT05639322).</p><p><strong>Findings: </strong>Between October 23, 2023, and March 31, 2025, 30 participants were randomized, and 26 (87%) completed 20-week follow-up. Most feasibility criteria, including consent, retention, data completeness, and absence of study-related serious adverse events, were met; adherence targets were partially met. Exploratory pain outcomes showed numerical improvement across groups, with clinically meaningful reductions observed for pain interference and pain intensity. Sixty-four adverse events were recorded, mostly mild and in ketamine-containing groups; no serious study-related adverse events occurred.</p><p><strong>Conclusions: </strong>Combined ketamine and psychotherapy was feasible and acceptably safe in this pilot trial, supporting evaluation in a larger efficacy-powered study.</p><p><strong>Funding: </strong>The study was funded by the St. Michael's Hospital Innovation Fund, The Canadian Pain Society Early Investigator Award and the Physician Services Incorporation Early Career Researcher Award.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101259"},"PeriodicalIF":13.3,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148761968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant oxaliplatin with S-1 (SOX) versus S-1 for stage II-III gastric cancer (CAPITAL): A randomized, open-label, phase 3 trial.","authors":"Run-Cong Nie, Shi Chen, Jin Wan, Xiao-Wei Sun, Wei-Qin Hong, Hong-Bo Wei, Wei Wang, Wen-Bin Zhang, Yan Zhao, Wei-Bin Zhang, Jing-Song Chen, Zu-Guang Wu, Cong Mai, Chun-Zai Feng, Shu-Qiang Yuan, Wei Wang, Hai-Bo Qiu, Yao Liang, Yuan-Xiang Guan, Yong-Ming Chen, Wen-Wu Liu, Chao Ding, Jun-Sheng Peng, Ying-Bo Chen, Zhi-Wei Zhou, Yuan-Fang Li","doi":"10.1016/j.medj.2026.101258","DOIUrl":"10.1016/j.medj.2026.101258","url":null,"abstract":"<p><strong>Background: </strong>Adjuvant chemotherapy following D2 gastrectomy constitutes the standard-of-care for resectable gastric or gastroesophageal junction (GEJ) carcinoma. The CAPITAL trial is a multicenter, randomized, phase 3 study, aiming to assess the efficacy and safety of adjuvant oxaliplatin plus S-1 (SOX) versus S-1 alone.</p><p><strong>Methods: </strong>Patients with histologically confirmed pathological stage II-III gastric or GEJ adenocarcinoma after gastrectomy with D2 lymphadenectomy were randomly assigned (1:1) to receive either the SOX regimen (n = 362) or the S-1 regimen (n = 362). The primary endpoint was overall survival. This study is registered with ClinicalTrials.gov (NCT01795027).</p><p><strong>Findings: </strong>The median follow-up was 74.0 months (interquartile range [IQR], 35.5-89.3). The 5-year overall survival rates were 70.9% (95% confidence interval [CI], 66.0-76.1) in the SOX group and 62.9% (95% CI, 57.8-68.5) in the S-1 group (hazard ratio [HR], 0.74; 95% CI, 0.58-0.95; p = 0.018). The 3- and 5-year disease-free survival rates were 71.2% (95% CI, 66.5-76.3) and 66.2% (95% CI, 61.2-71.6) in the SOX group, as compared with 65.1% (95% CI, 60.2-70.5) and 55.6% (95% CI, 50.4-61.3) in the S-1 group (HR, 0.76; 95% CI, 0.61-0.96). Treatment-related adverse events of grade 3-4 occurred in 87 (25%) of 349 patients in the SOX group and 45 (13%) of 347 patients in the S-1 group. The most common grade 3-4 adverse event was neutropenia, occurring in 44 (13%) of 349 patients in the SOX group and 23 (7%) of 347 patients in the S-1 group.</p><p><strong>Conclusions: </strong>The addition of adjuvant oxaliplatin to S-1 chemotherapy significantly improved overall survival and disease-free survival in patients with gastric cancer.</p><p><strong>Funding: </strong>This research was supported by the National Natural Science Foundation of China (82573092 and 82573387).</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101258"},"PeriodicalIF":13.3,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148761361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}